New targeted therapies for genetically linked skin diseases
Tuberous Sclerosis
- Topical Rapamycin could be used to treat facial angiofibromas (“Adenoma Sebaceum”) (link) (Archives of Dermatology, 2010)
Neurofibromatosis (Recklinghausen’s Disease)
- Mast cells play an important role
- The c-Kit receptor on mast cells is stimulated by mediators that are liberated by Schwann cells
- The activation of mast cells then induces the liberation of maediators that lead to proliferation of Schwann cells and the subsequent tumor formation.
- Imatinib inhibits c-Kit activation and could therefore play a role
Basal Cell Carcinoma (BCC)
- In Gorlin’s Syndrome as well as sporadic BCCs, mutations of the PTCH (Patched) gene have been found.
- This mutations leads to the overactivity of the hedgehog pathway and subsequent carcinoma formation.
- Inhibition of this pathway through inhibition of SMO (Smoothened) is possible with oral and topical substances (LDE 225 is an example…)
Progeria
- Mutations of the LMNA gene have been found
- Inhibition of the nuclear activation is possible with inhibitors of farnexytransferase
Recessive Dystrophic Epidermolysis Bullosa (EB)
- deficiency of collagen VII is responsible for this condition.
- It has been shown that injection of collagen VII into the wounds can reverse this phenomenon
- When applied topically, it has been shown to accelerate wound healing in mice.
CHILD syndrome (Congenital Hemidysplasia with Ichtyosiform Lesions and Limb Defects)
- Proteolysis of HMG Co-A is dependant on cholesterol. A lack of this leads subsequently to an abnormal Stratum Corneum.
- Topical formulations containing 2% lovastatin and 2% cholesterol have been shown to show good clinical results (link)
Epidermolysis Bullosa Simplex (EBS)
- Symptoms are due to a mutation and functional absence of keratin 14 (K14)
- Addition of K16 can compensate for this loss.
- Sulforaphane in Broccoli Sporouts could compensate for this loss by supplying K16 and K17.
Contributors:
Dr Christophe HSU – dermatologist. Geneva, Switzerland
Source of Information: SY 22. Paller A. Update on Genetic Disorders. 2012 (06) – 9th Spring Symposium of the EADV (European Academy of Dermatology and Venerology) – Verona, Italiy (Italia)
Category : Basal Cell Carcinoma (BCC) - Modifie le 06.10.2012Category : Carcinome Basocellulaire (CBC) - Modifie le 06.10.2012Category : CHILD syndrome - Modifie le 06.10.2012Category : Epidermolyse Bulleuse Dystrophique Récessive - Modifie le 06.10.2012Category : Epidermolyse Bulleuse Simple (Simplex) (EBS) - Modifie le 06.10.2012Category : Epidermolysis Bullosa Simplex (EBS) - Modifie le 06.10.2012Category : Neurofibromatose (Maladie de Recklinghausen) - Modifie le 06.10.2012Category : Neurofibromatosis (Recklinghausen's Disease) - Modifie le 06.10.2012Category : New targeted therapies for genetically linked skin diseases - Modifie le 06.10.2012Category : Nouvelles thérapies ciblées pour le traitement de maladies de la peau avec des anomalies génétiques - Modifie le 06.10.2012Category : progeria - Modifie le 06.10.2012Category : Recessive Dystrophic Epidermolysis Bullosa (EB) - Modifie le 06.10.2012Category : Sclérose Tubéreuse de Bourneville - Modifie le 06.10.2012Category : Syndrome de CHILD - Modifie le 06.10.2012Category : Tuberous Sclerosis - Modifie le 06.10.2012